|
Dendritic cell vaccine (DCVAC) combined with chemotherapy (CMT) in patients with newly diagnosed epithelial ovarian carcinoma (EOC) after primary debulking surgery (PDS): Biomarker exploratory analysis of a phase 2, open-label, randomized, multicenter trial. |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Janssen; Lilly; Merck Serono; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi; SERVIER |
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Janssen; Lilly; Merck Serono; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi; SERVIER |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono |
| |
|
No Relationships to Disclose |
| |
|
|
| |
|
|
| |
|
Employment - CureVac; Sotio |
Travel, Accommodations, Expenses - CureVac |
| |
|
|
| |
|
|
Stock and Other Ownership Interests - Sotio |
| |
|
|
Stock and Other Ownership Interests - Sotio |